<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312438791</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312438791</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Diagnostics of primary aldosteronism: is obligatory use of confirmatory tests justified?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Myśliwiec</surname><given-names>Janusz</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>żukowski</surname><given-names>Łukasz</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Grodzka</surname><given-names>Anna</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Piłaszewicz</surname><given-names>Agata</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Drągowski</surname><given-names>Szymon</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Górska</surname><given-names>Maria</given-names></name>
</contrib>
<aff id="aff1-1470320312438791">Department of Endocrinology, Diabetology and Internal Diseases, Medical University of Bialystok, Poland</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1470320312438791">Janusz Myśliwiec, Department of Endocrinology, Diabetology and Internal Diseases, Medical University of Bialystok, ul. M. Skłodowskiej-Curie 25, 15–276 Białystok, Poland. Email: <email>janusz.mysliwiec@umb.edu.pl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>3</issue>
<fpage>367</fpage>
<lpage>371</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1470320312438791">
<title>Introduction:</title>
<p>Assessment of the renin-angiotensin-aldosterone system has been recently granted a much greater role in the evaluation of patients with arterial hypertension. There is no single test efficient in selection of patients for second-step etiological investigation.</p>
</sec>
<sec id="section2-1470320312438791">
<title>Methods:</title>
<p>Altogether, 198 consecutive patients − 119 women (60%) and 79 men (40%) – hospitalized in years 2009–2011 at the Clinical Department of Endocrinology Medical University of Bialystok were diagnosed with primary aldosteronism. In each patient, plasma renin activity and plasma aldosterone concentration (basic and after 2 l NaCl infusion) were evaluated.</p>
</sec>
<sec id="section3-1470320312438791">
<title>Results:</title>
<p>The percentage of patients with plasma aldosterone concentration ≥15 ng/ml was 53 and the percentage of patients with plasma renin activity ≤0.1 ng/ml/h was 20. The percentage of patients screened for primary aldosteronism in which the aldosterone:renin ratio exceeded consecutive cut-offs of 20, 30, 40 and 50 were respectively 57, 45, 34 and 29. Among 15 patients in which plasma aldosterone concentration after infusion of 2 l of saline was ≥6.5 ng/dl (8.6%), 13 (6.6%) were diagnosed with primary aldosteronism.</p>
</sec>
<sec id="section4-1470320312438791">
<title>Conclusion:</title>
<p>The obligatory use of tests confirming autonomy of aldosterone secretion in patients screened for primary aldosteronism seems cost-effective in limiting the number of patients for further diagnosis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Aldosterone</kwd>
<kwd>renin</kwd>
<kwd>hypertension</kwd>
<kwd>primary aldosteronism</kwd>
<kwd>saline test</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1470320312438791" sec-type="intro">
<title>Introduction</title>
<p>The assessment of the renin-angiotensin-aldosterone system has been recently granted a much greater role in the evaluation of patients with arterial hypertension (AH). This was mainly due to the growing appreciation that primary aldosteronism (PA) is a much more common cause of hypertension than was previously thought. Recently published cross-sectional and prospective clinical studies have brought reliable data that PA is responsible for as many as 5–13% of AH cases and even up to over 20% in resistant AH.<sup><xref ref-type="bibr" rid="bibr1-1470320312438791">1</xref><xref ref-type="bibr" rid="bibr2-1470320312438791"/><xref ref-type="bibr" rid="bibr3-1470320312438791"/><xref ref-type="bibr" rid="bibr4-1470320312438791"/><xref ref-type="bibr" rid="bibr5-1470320312438791"/><xref ref-type="bibr" rid="bibr6-1470320312438791"/>–<xref ref-type="bibr" rid="bibr7-1470320312438791">7</xref></sup> The above data suggest an important place of screening tests for PA in AH patients, especially in young individuals, with severe hypertension, drug-resistant AH, AH with adrenal incidentaloma and/or with spontaneous or diuretic-induced hypokalemia.<sup><xref ref-type="bibr" rid="bibr1-1470320312438791">1</xref>,<xref ref-type="bibr" rid="bibr7-1470320312438791">7</xref>,<xref ref-type="bibr" rid="bibr8-1470320312438791">8</xref></sup> In over 60% of normokalemic patients who were confirmed to have PA, potassium concentration may no longer serve as a screening method.<sup><xref ref-type="bibr" rid="bibr1-1470320312438791">1</xref>,<xref ref-type="bibr" rid="bibr7-1470320312438791">7</xref></sup> That is why current clinical practice guidelines recommend obligatory screening for PA by measurement of the serum plasma aldosterone concentration (PAC)/plasma renin activity (PRA) aldosterone:renin ratio (ARR) among a much wider population of hypertensives than previously.<sup><xref ref-type="bibr" rid="bibr7-1470320312438791">7</xref></sup> However, cut-off points of ARR that were used among authors extend from 20 to 100; therefore, its clinical value is controversial.<sup><xref ref-type="bibr" rid="bibr1-1470320312438791">1</xref><xref ref-type="bibr" rid="bibr2-1470320312438791"/><xref ref-type="bibr" rid="bibr3-1470320312438791"/><xref ref-type="bibr" rid="bibr4-1470320312438791"/><xref ref-type="bibr" rid="bibr5-1470320312438791"/><xref ref-type="bibr" rid="bibr6-1470320312438791"/><xref ref-type="bibr" rid="bibr7-1470320312438791"/>–<xref ref-type="bibr" rid="bibr8-1470320312438791">8</xref></sup> In a recently published paper we have shown that ARR, at whichever cut-off point, is not effective enough to select patients for further evaluation.<sup><xref ref-type="bibr" rid="bibr9-1470320312438791">9</xref></sup> Positive screening for PA needs confirmatory testing to prove that aldosterone secretion is autonomic. Several testing procedures are used; however, saline infusion is the most common for its reliability and safety.<sup><xref ref-type="bibr" rid="bibr8-1470320312438791">8</xref></sup></p>
<p>Taking the above data into account, the objective of the present work was PRA, PAC and ARR assessment as criteria for diagnosis of PA and estimation of a role of confirmatory testing by saline infusion in the diagnostics process for PA.</p>
</sec>
<sec id="section6-1470320312438791" sec-type="materials|methods">
<title>Materials and methods</title>
<p>Retrospective analysis was carried out in a group of 198 consecutive patients who were hospitalized in years 2009–2011 at the Clinical Department of Endocrinology Medical University of Bialystok and were admitted in order to diagnose PA. This group consisted of 119 women (60%) aged 55 ± 12.6 years and 79 men (40%) aged 53 ± 20.6 years. In each patient, PAC and PRA, sodium and potassium plasma concentrations were evaluated. In 173 patients, urine concentration of catecholamine metabolites was assayed and in 162 patients diagnostics for hypercortisolemia was done. In patients with adrenal incidentaloma, 16 row computer tomography was performed with description of tissue density in Hounsfield’s scale. Before determination of PAC and PRA was performed, deficiency of potassium was corrected; diuretics and spironolactone were withdrawn for at least 4 weeks and β-adrenergic blockers, clonidine, methyldopa, dihydropiridine calcium channel antagonists, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and non-steroidal anti-inflammatory drugs were withdrawn for 2 weeks. All patients were given 2 l NaCl infusion as aldosterone secretion inhibiting factor. PAC was determined by the radioimmunoassay method with a RIAZENco kit (ZenTech, Belgium). The coefficient of variation (CV) was 5.3%, sensitivity 1.4 pg/ml and specificity 100%. PRA was assayed by the radioimmunoassay method with the use of a REN-CT2 (Radim Company, Italy). The incubation period of renin and angiotensinogen to generate angiotensin I for this assay was 90 min. For average PRA, a 1.6 ng/ml/h intra-assay precision CV was 10.0 and inter-assay precision CV was 5.6, sensitivity 0.018 ng/ml and specificity 100%. PRA, PAC and ARR were estimated twice in the subjects: first, in the morning after at least 2 h in an upright position and after 5–15 min sitting; second, in the morning maintaining a recumbent posture before being given 2 l of 0.9% saline infusion over a 4 h period. Third, PAC measurement was taken after a saline overload. The cut-off value for PAC to confirm PA was 6.5 ng/ml based on receiver operating characteristic (ROC) curve analysis. Determination of urine methanephrine and normethanephrine was performed by the immunoassay method using Nephrines Urine kits of Biosource (Belgium). Values expectations: methanephrins &lt;350 ug/day; normethanephrines &lt;600 ug/day. Sensitivity: methanephrins 5 ng/ml; normethanephrines 13 ng/mI. CV for methanephrins 5.2%, for normethanephrines 12.2%. Cortisol was evaluated by the chemiluminescentic method with Architect System kits (Abbott, Germany): sensitivity ≤1 μg/dl, CV 20%.</p>
</sec>
<sec id="section7-1470320312438791" sec-type="results">
<title>Results</title>
<p>PRA and PAC was assayed in 140 patients (70%) with adrenal incidentaloma, 38 patients (19%) with drug-resistant hypertension, 18 (9%) with early-onset hypertension (≤40 years) and four with hypertension and hypokaliemia (1.8%) (<xref ref-type="fig" rid="fig1-1470320312438791">Figure 1</xref>). The percentage of patients with PAC ≥15 ng/ml is shown in <xref ref-type="fig" rid="fig2-1470320312438791">Figure 2</xref> and the proportional percentage of patients with PRA ≤0.1 ng/ml/h is illustrated in <xref ref-type="fig" rid="fig3-1470320312438791">Figure 3</xref>. <xref ref-type="fig" rid="fig4-1470320312438791">Figure 4</xref> shows the percentage of patients screened for PA, in which sitting ARR exceeded consecutive cut-offs of 20, 30, 40 and 50. In 48 patients (24%), three criteria considered as suggestive for PA (PAC ≥15 ng/dl, PRA ≤0.1 ng/ml/h, ARR &gt;20) were found. ROC curves for ARR1 (sitting), ARR2 (in a supine position) and post-NaCl PAC are depicted in <xref ref-type="fig" rid="fig5-1470320312438791">Figure 5</xref>.The area under the curve for ARR1, ARR2 and post-NaCl PAC was respectively: 0.74, 0.84 and 0.97. Suggested cut-off points for ARR1, ARR2 and post-NaCl PAC were respectively 321, 287 and 6.5 ng/ml. In <xref ref-type="fig" rid="fig6-1470320312438791">Figure 6</xref>, sensitivity and specificity curves for post-NaCl PAC are shown. <xref ref-type="table" rid="table1-1470320312438791">Table 1</xref> summarizes the characteristics of 13 patients in which PAC after infusion of 2 l of saline was ≥6.5 ng/dl (6.6%) and therefore PA was confirmed. In three of these patients, unilateral adrenalectomy was performed. In one of them normotension without drugs was achieved 4 months later and in two patients hypotensive drugs were still needed, although in reduced doses. In 10 patients, spironolactone was started after PA diagnosis with at least partial efficacy on blood pressure and potassium concentration.</p>
<fig id="fig1-1470320312438791" position="float">
<label>Figure 1.</label>
<caption>
<p>Percentage of patients with particular indications who were diagnosed with primary aldosteronism (in comparison to the whole group; <italic>n</italic>=198).</p>
</caption>
<graphic xlink:href="10.1177_1470320312438791-fig1.tif"/>
</fig>
<fig id="fig2-1470320312438791" position="float">
<label>Figure 2.</label>
<caption><p>Percentage of patients with plasma aldosterone concentration (PAC) ≥15 ng/dl.</p></caption>
<graphic xlink:href="10.1177_1470320312438791-fig2.tif"/>
</fig>
<fig id="fig3-1470320312438791" position="float">
<label>Figure 3.</label>
<caption><p>Percentage of patients with plasma renin activity (PRA) &lt;0.1 ng/ml/h.</p></caption>
<graphic xlink:href="10.1177_1470320312438791-fig3.tif"/>
</fig>
<fig id="fig4-1470320312438791" position="float">
<label>Figure 4.</label>
<caption><p>Percentage of patients diagnosed for primary aldosteronism (<italic>n</italic>=198), in which sitting plasma aldosterone concentration/plasma renin activity ratio exceeded consecutive cut-offs.</p></caption>
<graphic xlink:href="10.1177_1470320312438791-fig4.tif"/>
</fig>
<fig id="fig5-1470320312438791" position="float">
<label>Figure 5.</label>
<caption><p>Receiver operating characteristic curves of aldosterone/renin ratio (ARR1, upright; ARR2, in supine position) and post-NaCl plasma aldosterone concentration (PAC; <italic>n</italic>=198).</p></caption>
<graphic xlink:href="10.1177_1470320312438791-fig5.tif"/>
</fig>
<fig id="fig6-1470320312438791" position="float">
<label>Figure 6.</label>
<caption><p>Sensitivity and specificity of post-NaCl plasma aldosterone concentration (PAC) (<italic>n</italic>=198).</p></caption>
<graphic xlink:href="10.1177_1470320312438791-fig6.tif"/>
</fig>
<table-wrap id="table1-1470320312438791" position="float">
<label>Table 1.</label>
<caption><p>Characteristics of 13 patients with plasma aldosterone concentration (PAC) ≥6.5 ng/dl after infusion of 2 l of NaCl (considered as confirmation of primary aldosteronism (PA))</p></caption>
<graphic alternate-form-of="table1-1470320312438791" xlink:href="10.1177_1470320312438791-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Age &amp; sex</th>
<th align="left">Indications</th>
<th align="left">Adrenal tumours (mm)</th>
<th align="left">PRA (ng/ml/h)</th>
<th align="left">PAC (ng/dl)</th>
<th align="left">ARR</th>
<th align="left">Post-NaCl PAC (ng/dl)</th>
<th align="left">Diagnosis &amp; treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55 <italic>m</italic></td>
<td>DRH</td>
<td>no</td>
<td><bold>0.7/0.7</bold></td>
<td><bold>22/19</bold></td>
<td><bold>31/</bold>27</td>
<td><bold>7.4</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>2</td>
<td>57 <italic>f</italic></td>
<td>AI</td>
<td>L-15/45HU</td>
<td><bold>0.15/0.9</bold></td>
<td>8/11</td>
<td><bold>53/122</bold></td>
<td><bold>7.8</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>R-18/25HU</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>3</td>
<td>69 <italic>f</italic></td>
<td>AI, DRH</td>
<td>L-22/8HU</td>
<td><bold>1.0/0.3</bold></td>
<td><bold>24/33</bold></td>
<td><bold>240/110</bold></td>
<td><bold>8.8</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>4</td>
<td>66 <italic>f</italic></td>
<td>AI</td>
<td>L-10/13HU</td>
<td><bold>1.0/0.5</bold></td>
<td><bold>38/</bold>13</td>
<td><bold>38/</bold>26</td>
<td><bold>9.5</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>5</td>
<td>67 <italic>m</italic></td>
<td>AI, DRH</td>
<td>R-26/10HU</td>
<td><bold>0.8/1.0</bold></td>
<td><bold>29/40</bold></td>
<td><bold>36/40</bold></td>
<td><bold>9.6</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>6</td>
<td>66 <italic>m</italic></td>
<td>AI, ↓K</td>
<td>L-15mm/8HU</td>
<td><bold>0.03/0.03</bold></td>
<td><bold>15/16</bold></td>
<td><bold>500/533</bold></td>
<td><bold>10.6</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>R-16mm/7HU</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>7</td>
<td>54 <italic>f</italic></td>
<td>↓K</td>
<td>no</td>
<td><bold>0.1/0.1</bold></td>
<td><bold>53/26</bold></td>
<td><bold>533/200</bold></td>
<td><bold>11.4</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>8</td>
<td>40 <italic>m</italic></td>
<td>AI, EOH</td>
<td>L-17mm/11HU</td>
<td><bold>0.1/0.08</bold></td>
<td><bold>24/16</bold></td>
<td><bold>120/200</bold></td>
<td><bold>14.6</bold></td>
<td>PA→surgery</td>
</tr>
<tr>
<td>9</td>
<td>64 <italic>f</italic></td>
<td>AI, ↓K</td>
<td>L-20mm/8HU</td>
<td><bold>0.1/0.06</bold></td>
<td><bold>33/17</bold></td>
<td><bold>333/283</bold></td>
<td><bold>16.2</bold></td>
<td>PA→spiro<sup><xref ref-type="table-fn" rid="table-fn2-1470320312438791">a</xref></sup></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>R-22mm/4HU</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>10</td>
<td>56 <italic>f</italic></td>
<td>DRH</td>
<td>no</td>
<td><bold>0.02/0.03</bold></td>
<td><bold>46/27</bold></td>
<td><bold>2300/900</bold></td>
<td><bold>17.0</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>11</td>
<td>44 <italic>f</italic></td>
<td>AI, EOH</td>
<td>L-14&amp;17mm/5HU</td>
<td><bold>0.02/0.07</bold></td>
<td><bold>28/33</bold></td>
<td><bold>1400/471</bold></td>
<td><bold>19.9</bold></td>
<td>PA→surgery</td>
</tr>
<tr>
<td>12</td>
<td>64 <italic>f</italic></td>
<td>AI</td>
<td>L-11mm/-5HU</td>
<td><bold>0.03/0.1</bold></td>
<td><bold>40/33</bold></td>
<td><bold>1100/400</bold></td>
<td><bold>28.3</bold></td>
<td>PA→spiro</td>
</tr>
<tr>
<td>13</td>
<td>48 <italic>m</italic></td>
<td>AI, EOH, ↓K</td>
<td>L-7&amp;8mm/5HU</td>
<td><bold>0.01/0.01</bold></td>
<td><bold>96/39</bold></td>
<td><bold>9600/3900</bold></td>
<td><bold>38.2</bold></td>
<td>PA→surgery</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>R-15mm/6HU</td>
<td/>
<td/>
<td/>
<td/>
<td>PA→surgery</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320312438791">
<p>PRA, plasma renin activity; ARR, aldosterone:renin ratio; PAC/plasma renin activity (PRA) quotient (first value, sitting; second value, supine); AI, adrenal incidentaloma; DRH, drug-resistant hypertension; ↓K- hypokaliemia; EOH, early onset hypertension; L/R, left/right; HU,Hounsfield units; spiro, spironolactone; AVS, adrenal veins sampling.</p>
</fn>
<fn id="table-fn2-1470320312438791">
<label>a</label>
<p>PA patient with proven lateralization in AVS, who finally did not show unilateral adrenalectomy, normotensive and normokaliemic on spironolactone and cilazapril.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-1470320312438791" sec-type="discussion">
<title>Discussion</title>
<p>Based on the results of PAC, PRA, ARR and post-saline PAC values in the context of clinical conditions, we diagnosed PA in 6.6% of the screened patients. This percentage is comparable with other recently published studies in which PA prevalence was 5–20% in patients with AH and predisposing conditions.<sup><xref ref-type="bibr" rid="bibr3-1470320312438791">3</xref><xref ref-type="bibr" rid="bibr4-1470320312438791"/><xref ref-type="bibr" rid="bibr5-1470320312438791"/>–<xref ref-type="bibr" rid="bibr6-1470320312438791">6</xref></sup> However, insofaras the majority of patients in our sample, the criterion used to diagnose for PA was adrenal incidentaloma (70%), with probability of PA estimated at 1–1.5%, the percentage of PA in our study is relatively high.<sup><xref ref-type="bibr" rid="bibr10-1470320312438791">10</xref>,<xref ref-type="bibr" rid="bibr11-1470320312438791">11</xref></sup></p>
<p>Sitting ARR is recommended by the Endocrine Society’s guidelines as the most reliable means of screening for PA, as it was shown to be superior to potassium or aldosterone (both of lower sensitivity) or renin measurement (less specific).<sup><xref ref-type="bibr" rid="bibr7-1470320312438791">7</xref>,<xref ref-type="bibr" rid="bibr12-1470320312438791">12</xref>,<xref ref-type="bibr" rid="bibr13-1470320312438791">13</xref></sup> In our study, the percentage of patients with PAC ≥15 ng/ml was 53 and percentage of patients with PRA ≤0.1 ng/ml/h was 24, reflecting inefficiency in the screening tests. Lack of uniformity in diagnostic protocols and assay methods for ARR measurement has been associated with a substantial variability in cut-off values used by different groups, ranging from 20 to 100.<sup>2, 14–18</sup> Furthermore, a large percentage of false positive and negative ARR values was shown to be related to unsatisfactory sensitivity and specificity of assays for both renin and aldosterone, as well as with an influence of numerous medications.<sup><xref ref-type="bibr" rid="bibr19-1470320312438791">19</xref><xref ref-type="bibr" rid="bibr20-1470320312438791"/>–<xref ref-type="bibr" rid="bibr21-1470320312438791">21</xref></sup> In our study, the percentage of patients screened for PA in which sitting ARR exceeded consecutive cut-offs of 20, 30, 40 and 50 was respectively: 57, 45, 34 and 29. Similar percentages of false positives were obtained in our previous sample of patients screened for PA.<sup><xref ref-type="bibr" rid="bibr9-1470320312438791">9</xref></sup></p>
<p>In several centers elevated aldosterone levels accompanied by elevated ARR is an established positive screening test for PA.<sup><xref ref-type="bibr" rid="bibr22-1470320312438791">22</xref></sup> Some investigators do not use a cut-off point for PAC but consider a greater likelihood of a false positive ARR when renin levels are low.<sup><xref ref-type="bibr" rid="bibr23-1470320312438791">23</xref></sup> The findings of several studies are against a formal cut-off level for aldosterone.<sup><xref ref-type="bibr" rid="bibr24-1470320312438791">24</xref>,<xref ref-type="bibr" rid="bibr25-1470320312438791">25</xref></sup> Moreover, ARR is mathematically highly dependent on renin, which was increased in 15 and decreased in 25% of patients with essential hypertension as well as in the elderly.<sup><xref ref-type="bibr" rid="bibr26-1470320312438791">26</xref>,<xref ref-type="bibr" rid="bibr27-1470320312438791">27</xref></sup></p>
<p>None of the current available tests serve as a ’gold standard’ method of detection because of unsatisfactory sensitivity and specificity of assays for both renin and aldosterone and numerous conditions that may influence them.<sup><xref ref-type="bibr" rid="bibr28-1470320312438791">28</xref></sup> Also their combination is not usually conclusive. In our present study, in as many as 48 patients (24%) three criteria considered as suggestive for PA (PAC ≥15 ng/dl, PRA ≤0.1 ng/ml/h, ARR &gt;20) were found. Four testing procedures (oral sodium loading, saline infusion, fludrocortisone suppression and captopril challenge) are in use and there is currently insufficient direct evidence to recommend one over the others. However, the most commonly used is the saline infusion test and the captopril test is of lesser value.<sup><xref ref-type="bibr" rid="bibr29-1470320312438791">29</xref></sup> It should be noted that confirmatory tests with oral or i.v. sodium loading should be administered with caution in patients with uncontrolled hypertension or congestive heart failure.</p>
<p>However, measurement of PRA and PAC as a screening tool (regardless of ARR) is still important because it does exclude patients with obvious secondary aldosteronism (elevated PRA) from further testing. Furthermore, it is important to note that patients with secondary aldosteronism may not suppress aldosterone with saline.</p>
<p>Based on ROC curves analysis of sitting and recumbent ARR and post-NaCl PAC, we found that the saline infusion test at the cut-off point for PAC 6.5 ng/dl, at specificity 97% and sensitivity 93% is a potent tool for PA confirmation. A similar value (7.0 ng/ml) was used in previously published papers showing sensitivity of 83–88% and a specificity of 75–100% when evaluated by cases with ARR more than 40 ng/dl per ng/ml/h.<sup><xref ref-type="bibr" rid="bibr1-1470320312438791">1</xref>,<xref ref-type="bibr" rid="bibr30-1470320312438791">30</xref></sup></p>
<p>In summary, the results of the present study suggest that the obligatory use of tests confirming autonomy of aldosterone secretion in patients being screened for PA seems cost-effective in limiting the number of patients for further investigations.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of Interest</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312438791">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>GP</given-names></name>
<name><surname>Bernini</surname><given-names>G</given-names></name>
<name><surname>Caliumi</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients</article-title>. <source>J Am Coll Cardiol</source> <year>2006</year>; <volume>48</volume>: <fpage>2293</fpage>–<lpage>3000</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312438791">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mulatero</surname><given-names>P</given-names></name>
<name><surname>Stowasser</surname><given-names>M</given-names></name>
<name><surname>Loh</surname><given-names>KC</given-names></name><etal/>
</person-group>. <article-title>Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents</article-title>. <source>J Clin Endocrinol Metab</source> <year>2004</year>; <volume>89</volume>: <fpage>1045</fpage>–<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312438791">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowasser</surname><given-names>M</given-names></name>
<name><surname>Gordon</surname><given-names>RD</given-names></name>
<name><surname>Gunasekera</surname><given-names>TG</given-names></name>
<etal/>
</person-group>. <article-title>High rate of detection of primary aldosteronism including surgically treatable forms, after non selective screening of hypertensive patients</article-title>. <source>J Hypertens</source> <year>2003</year>; <volume>21</volume>: <fpage>2149</fpage>–<lpage>2157</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312438791">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calhoun</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Resistant or difficult-to-treat hypertension</article-title>. <source>J Clin Hypertens (Greenwich)</source> <year>2006</year>; <volume>8</volume>: <fpage>181</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312438791">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Douma</surname><given-names>S</given-names></name>
<name><surname>Petidis</surname><given-names>K</given-names></name>
<name><surname>Doumas</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study</article-title>. <source>Lancet</source> <year>2008</year>; <volume>371</volume>: <fpage>1921</fpage>–<lpage>1926</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312438791">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mulatero</surname><given-names>P</given-names></name>
<name><surname>Williams</surname><given-names>TA</given-names></name>
<name><surname>Milan</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism</article-title>. <source>Hypertension</source> <year>2002</year>; <volume>40</volume>: <fpage>897</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312438791">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>GP</given-names></name>
<name><surname>Bernini</surname><given-names>G</given-names></name>
<name><surname>Desideri</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Renal damage in primary aldosteronism: Results of the PAPY Study</article-title>. <source>Hypertension</source> <year>2006</year>; <volume>48</volume>: <fpage>232</fpage>–<lpage>238</lpage></citation>
</ref>
<ref id="bibr8-1470320312438791">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Funder</surname><given-names>JW</given-names></name>
<name><surname>Carey</surname><given-names>RM</given-names></name>
<name><surname>Fardella</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source> <year>2008</year>; <volume>93</volume>: <fpage>3266</fpage>–<lpage>3281</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312438791">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mysliwiec</surname><given-names>J</given-names></name>
<name><surname>Zukowski</surname><given-names>L</given-names></name>
<name><surname>Grodzka</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Problems in diagnostics of primary aldosteronism – analysis of the own data</article-title>. <source>Endokrynol Pol</source> <year>2010</year>; <volume>61</volume>: <fpage>2</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312438791">
<label>10.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Kaplan</surname><given-names>NM</given-names></name>
<name><surname>Victor</surname><given-names>RG</given-names></name>
</person-group>. <article-title>Primary aldosteronism. In Kaplan’s clinical hypertension, chapter 11</article-title>, <edition>10th ed.</edition> <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>LWW</publisher-name>, <year>2010</year>, pp. <fpage>339</fpage>–<lpage>357</lpage>.</citation>
</ref>
<ref id="bibr11-1470320312438791">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mantero</surname><given-names>F</given-names></name>
<name><surname>Terzolo</surname><given-names>M</given-names></name>
<name><surname>Arnaldi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology</article-title>. <source>J Clin Endocrinol Metab</source> <year>2000</year>; <volume>85</volume>(<issue>2</issue>): <fpage>637</fpage>–<lpage>644</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312438791">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hiramatsu</surname><given-names>K</given-names></name>
<name><surname>Yamada</surname><given-names>T</given-names></name>
<name><surname>Yukimura</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients</article-title>. <source>Arch Intern Med</source> <year>1981</year>; <volume>141</volume>: <fpage>1589</fpage>–<lpage>1593</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312438791">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowasser</surname><given-names>M</given-names></name>
<name><surname>Gordon</surname><given-names>RD</given-names></name>
<name><surname>Gunasekera</surname><given-names>TG</given-names></name>
<etal/>
</person-group>. <article-title>High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non-selective’ screening of hypertensive patients</article-title>. <source>J Hypertens</source> <year>2003</year>; <volume>21</volume>: <fpage>2149</fpage>–<lpage>2157</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312438791">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gordon</surname><given-names>RD</given-names></name>
<name><surname>Stowasser</surname><given-names>M</given-names></name>
<name><surname>Tunny</surname><given-names>TJ</given-names></name>
<etal/>
</person-group>. <article-title>High incidence of primary aldosteronism in 199 patients referred with hypertension</article-title>. <source>Clin Exp Pharmacol Physiol</source> <year>1994</year>; <volume>21</volume>: <fpage>315</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312438791">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loh</surname><given-names>KC</given-names></name>
<name><surname>Koay</surname><given-names>ES</given-names></name>
<name><surname>Khaw</surname><given-names>MC</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore</article-title>. <source>J Clin Endocrinol Metab</source> <year>2000</year>; <volume>85</volume>: <fpage>2854</fpage>–<lpage>2859</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312438791">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gallay</surname><given-names>BJ</given-names></name>
<name><surname>Ahmad</surname><given-names>S</given-names></name>
<name><surname>Xu</surname><given-names>L</given-names></name>
<name><surname>Toivola</surname><given-names>B</given-names></name>
<name><surname>Davidson</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio</article-title>. <source>Am J Kidney Dis</source> <year>2001</year>; <volume>37</volume>: <fpage>699</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312438791">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tiu</surname><given-names>SC</given-names></name>
<name><surname>Choi</surname><given-names>CH</given-names></name>
<name><surname>Shek</surname><given-names>CC</given-names></name>
<etal/>
</person-group>. <article-title>The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristics under different conditions of blood sampling</article-title>. <source>J Clin Endocrinol Metab</source> <year>2005</year>; <volume>90</volume>: <fpage>72</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312438791">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>WF</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Primary aldosteronism: Update on diagnosis and treatment</article-title>. <source>Endocrinologist</source> <year>1997</year>; <volume>7</volume>: <fpage>213</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312438791">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schirpenbach</surname><given-names>C</given-names></name>
<name><surname>Seiler</surname><given-names>L</given-names></name>
<name><surname>Maser-Gluth</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: Comparison to radioimmunoassays with and without extraction steps</article-title>. <source>Clin Chem</source> <year>2006</year>; <volume>52</volume>: <fpage>1749</fpage>–<lpage>1755</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312438791">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schwartz</surname><given-names>GL</given-names></name>
<name><surname>Turner</surname><given-names>ST</given-names></name>
</person-group>. <article-title>Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity</article-title>. <source>Clin Chem</source> <year>2005</year>; <volume>51</volume>: <fpage>386</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312438791">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanabe</surname><given-names>A</given-names></name>
<name><surname>Naruse</surname><given-names>M</given-names></name>
<name><surname>Takagi</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism</article-title>. <source>J Clin Endocrinol Metab</source> <year>2003</year>; <volume>88</volume>: <fpage>2489</fpage>–<lpage>2494</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312438791">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowasser</surname><given-names>M</given-names></name>
<name><surname>Gordon</surname><given-names>RD</given-names></name>
</person-group>. <article-title>The aldosterone-renin ratio for screening for primary aldosteronism</article-title>. <source>Endocrinologist</source> <year>2004</year>; <volume>14</volume>: <fpage>267</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312438791">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Young</surname><given-names>WF</given-names></name>
</person-group>. <article-title>Primary aldosteronism: renaissance of a syndrome</article-title>. <source>Clin Endocrinol (Oxf)</source> <year>2007</year>; <volume>66</volume>: <fpage>607</fpage>–<lpage>618</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312438791">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mosso</surname><given-names>L</given-names></name>
<name><surname>Carvajal</surname><given-names>C</given-names></name>
<name><surname>Gonzalez</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Primary aldosteronism and hypertensive disease</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>42</volume>: <fpage>161</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312438791">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stowasser</surname><given-names>M</given-names></name>
<name><surname>Gordon</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Primary aldosteronism: Careful investigation is essential and rewarding</article-title>. <source>Mol Cell Endocrinol</source> <year>2004</year>; <volume>217</volume>: <fpage>33</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312438791">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montori</surname><given-names>VM</given-names></name>
<name><surname>Schwartz</surname><given-names>GL</given-names></name>
<name><surname>Chapman</surname><given-names>AB</given-names></name>
<etal/>
</person-group>. <article-title>Validity of the aldosterone-renin ratio used to screen for primary aldosteronism</article-title>. <source>Mayo Clin Proc</source> <year>2001</year>; <volume>76</volume>: <fpage>877</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr27-1470320312438791">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bühler</surname><given-names>FR</given-names></name>
<name><surname>Bolli</surname><given-names>P</given-names></name>
<name><surname>Kiowski</surname><given-names>W</given-names></name>
</person-group>. <article-title>Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients</article-title>. <source>Am J Med</source> <year>1984</year>; <volume>77</volume>: <fpage>36</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312438791">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sagnella</surname><given-names>GA</given-names></name>
</person-group>. <article-title>Why is plasma renin activity lower in populations of African origin?</article-title> <source>J Hum Hypertens</source> <year>2001</year>; <volume>15</volume>: <fpage>17</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312438791">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Westerdahl</surname><given-names>C</given-names></name>
<name><surname>Bergenfelz</surname><given-names>A</given-names></name>
<name><surname>Isaksson</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Captopril suppression: Limitations for confirmation of primary aldosteronism</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2011</year>; <volume>12</volume>: <fpage>326</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312438791">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giacchetti</surname><given-names>G</given-names></name>
<name><surname>Ronconi</surname><given-names>V</given-names></name>
<name><surname>Lucarelli</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: Need for a standardized protocol</article-title>. <source>J Hypertens</source> <year>2006</year>; <volume>24</volume>: <fpage>737</fpage>–<lpage>745</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>